# OnCo record nct05219500 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05219500/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05219500", "NCT05219500" ;
  schema:name "Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST)."@en ;
  schema:alternateName "TATCIST"@en ;
  schema:description "A phase 2 trial of FPI-2265 in prostate cancer, run by Fusion Pharmaceuticals Inc., active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05219500/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05219500> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2021-12-16" ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/prostate-mcrpc/> ;
  onco:drugs <https://onco.cc/drugs/fpi-2265/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/> .